Hutchmed (China) Limited Share Option Scheme and Long Term Incentive Plan (4231Z)
14 Setembro 2022 - 7:00AM
UK Regulatory
TIDMHCM
RNS Number : 4231Z
Hutchmed (China) Limited
14 September 2022
Grant of Share Options under Share Option Scheme and Awards
under Long Term Incentive Plan
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday ,
September 14, 2022: HUTCHMED (China) Limited ("HUTCHMED")
(Nasdaq/AIM: HCM; HKEX: 13) announces that on September 13, 2022,
it granted share options under the Share Option Scheme adopted by
HUTCHMED in 2015 (the "Share Option Scheme") and conditional awards
("LTIP Awards") under the Long Term Incentive Plan adopted by
HUTCHMED in 2015 ("LTIP").
Aimed at attracting and retaining top talent, the Remuneration
Committee of HUTCHMED appointed an independent advisor to conduct a
compensation benchmarking research on selected peer group
companies. The Remuneration Committee comprehensively reviewed the
compensation and share-based incentives policies of HUTCHMED and
its subsidiaries (the "Group") and established an attractive policy
to ensure the Group is able to recruit and retain top talent.
Vesting of share-based awards under the policy is in line with that
peer group.
HUTCHMED granted share options under its Share Option Scheme to
three employees to subscribe for a total of 1,750,000 ordinary
shares with par value US$0.10 each in the share capital of the
Company ("Ordinary Shares") represented by 350,000 American
Depositary Shares ("ADSs") (each equivalent to five Ordinary
Shares) subject to the acceptance of the grantee. Details of such
share options granted are as follows:
Date of grant : September 13, 2022
Exercise price of share options : US$13.14 per ADS (equivalent to
granted HK$20.50 per Ordinary Share at the
conversion rate HK$7.8=US$1) (such
exercise price has been determined
by reference to the price of the
Ordinary Shares on The Stock Exchange
of Hong Kong Limited ("HKEX"))
Number of share options granted : 1,750,000 represented by 350,000
ADSs (five share options shall entitle
the holder thereof to subscribe
for one ADS)
Closing market price of Ordinary : US$13.14 per ADS (equivalent to
Shares at HKEX on the date of HK$20.50 per Ordinary Share at the
grant conversion rate HK$7.8=US$1)
Validity period of the share : From September 13, 2022 to September
options 12, 2032
Vesting period of the share options : The share options will vest at 25%
on each of the first, second, third
and fourth anniversaries of the
date of grant of the share options.
At the same time, HUTCHMED also granted two employees of the
Group with non-performance based LTIP Awards and 135 employees of
the Group with performance-based LTIP Awards.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery and global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. It has more than 4,900 personnel across all
its companies, at the center of which is a team of about 1,800 in
oncology/immunology. Since inception it has advanced 13 cancer drug
candidates from in-house discovery into clinical studies around the
world, with its first three oncology drugs now approved and
marketed in China. For more information, please visit:
www.hutch-med.com or follow us on LinkedIn.
Forward -Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
HUTCHMED's filings with the U.S. Securities and Exchange
Commission, on AIM and on HKEX. HUTCHMED undertakes no obligation
to update or revise the information contained in this announcement,
whether as a result of new information, future events or
circumstances or otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury +1 (917) 570 7340 (Mobile) | bmiles@soleburystrat.com
Europe - Ben Atwell / Alex Shaw, FTI +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
HUTCHMED@fticonsulting.com
Asia - Zhou Yi, Brunswick +852 97 83 6894 (Mobile) | HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGRGDCCUBDGDS
(END) Dow Jones Newswires
September 14, 2022 06:00 ET (10:00 GMT)
HUTCHMED China (AQSE:HCM.GB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
HUTCHMED China (AQSE:HCM.GB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
